J Rheum Dis 2019; 26(3): 165-178  
The Role of Autoantibodies in Idiopathic Inflammatory Myopathies
In Seol Yoo, Jinhyun Kim
Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea
Correspondence to: Jinhyun Kim http://orcid.org/0000-0001-5235-2612
Department of Internal Medicine, Chungnam National University College of Medicine, 266 Munhwa-ro, Jung-gu, Daejeon 35015, Korea. E-mail:jkim@cnuh.co.kr
Received: March 6, 2019; Revised: March 20, 2019; Accepted: March 21, 2019; Published online: July 1, 2019.
© Korean College of Rheumatology. All rights reserved.

This is a open Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune muscle diseases with systemic involvement. Patients with IIM present with varying degrees of muscle disease, cutaneous manifestations, and internal organ involvement. The diagnosis and classification of IIM is based primarily on the classification system composed of clinical features, laboratory value and muscle biopsy. In addition, the identification and characterization of myositis-related autoantibodies can help diagnosis and classification. Recently, many studies have also demonstrated that the physician can define the clinical syndromes, establish treatment strategy and predict outcomes based on the patients’ myositis-specific autoantibodies (MSA) and myositis-associated antibodies (MAA) profiles. MSAs are found exclusively in IIMs and facilitate the identification of subsets of patients with relatively homogeneous clinical features. MAAs are frequently found in association with other MSA; however, they may also be detected in various connective diseases.
Keywords: Myositis, Dermatomyositis, Polymyositis, Antinuclear antibody

This Article